October 2017

Feature

Research Reports

Community Oncologists‚ Perception and Adaptability to Emerging Chimeric Antigen T-Cell Therapy

10/16/2017

Bruce A. Feinberg , DO;

Chadi Nabhan , MD, MBA, FACP;

Yolaine J. Jeune-Smith , PhD;

Peter Klinefelter , BA;

Jennifer Fillman , MBA;

Abstract: The Oncologic Drugs Advisory Committee recently voted 10-0 recommending to the Food and Drug Administration (FDA) the approval of the first chimeric antigen receptor T (CAR-T) therapy. We sought to better...

...

10/16/2017

Journal of Clinical Pathways

Perspectives

Potential for Clinical Pathways in Symptom Management

10/16/2017

Gena Cook , BA;

Abstract: Clinical pathways are one of the main tools employed across health care to manage quality and consistency. Pathways are also useful for the reduction of variability in cancer care. Clinical pathways in...

...

10/16/2017

Journal of Clinical Pathways

Column

Editor's Page

Integrating Gene Therapy Into Value-Based Care

10/16/2017

Winston Wong , PharmD;

Medical advances emerge swiftly, and sometimes surprisingly. The rapid number of new products approved by the Food and Drug Administration (FDA) for the treatment and care of patients with cancer perfectly...

...

10/16/2017

Journal of Clinical Pathways

Clinical Pathways GPS

Looking for Leadership in Developing Pathways

10/16/2017

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Scott Guerin , PhD;

A clinical pathway can be defined as an “optimal sequencing and timing of interventions by physicians, nurses, and other staff for a particular diagnosis or procedure.” As organizations new to pathways look to...

A...

10/16/2017

Journal of Clinical Pathways

Pharma Insights

Orphan Drugs: Understanding the Payer Perspective

10/16/2017

Hetty A. Lima , BSPharm, RPh, FASHP;

Kellie Rademacher , PharmD;

New drugs for orphan and rare diseases have the potential to positively impact the lives of patients where historically few or no treatments had been available to manage the disease. The passage of the Orphan Drug...

New...

10/16/2017

Journal of Clinical Pathways

News

Conference Coverage

Clinical Pathways Congress

10/16/2017

JCP Editors

The second annual Clinical Pathways Congress (CPC) was held over the weekend of September 8th in Washington, DC. A diverse group of stakeholders representing patients, providers, payers, and the pharmaceutical...

The...

10/16/2017

Journal of Clinical Pathways

Insights

Interview

Institutional Approaches to Value-Based Care

10/16/2017

Oncology has emerged as a subspecialty particularly amenable to clinical pathways. As value-based care continues to gain in prominence and importance in practices across the United States, individual providers...

...

10/16/2017

Journal of Clinical Pathways

Interview

Breakthrough Care Comes at a Cost

10/16/2017

JCP Editors

Gene therapy has captivated the oncology treatment community for years. After promising results in clinical trials, the first generation of gene therapies are being introduced to the market following Food and Drug...

Gene...

10/16/2017

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Editorial Correspondence

October 2017

Feature

Column

News

Insights

Current Issue

Special Reports

Subscribe

Volume 3

Specialties

Events

Year Round Education

HMP Global Products